NewsRoom Articles - Page 46 of 214

WednesdayFeb 14, 2024 10:00 am

Study Links Ramadan Fasting to Lower Risk of Chronic Disease Development

A recent study has revealed that Ramadan fasting may be associated with a lower risk of developing chronic diseases. Published in the “American Journal of Clinical Nutrition,” the study found that Ramadan fasting was linked with a significant reduction in the risk of breast, colorectal and lung cancers. Researchers collected data from 72 participants from the London Ramadan Study (LORANS), an observational cohort of 140 Muslims who follow the annual Ramadan fast. Ramadan typically involves avoiding all food and drink from before the day’s first light till the sun sets on a specific set of days every year. The researchers…

TuesdayFeb 13, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)

Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited CNM-Au8(R) has demonstrated remarkable efficacy across various nervous system cell types, with its ability to target fundamental deficiencies associated with dying neurons Gold nanocrystals found in CNM-Au8 act as miniature mitochondria, providing neurons with much-needed ATP energy while simultaneously converting toxic reactive oxygen species into harmless compounds Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is working on a potentially groundbreaking…

MondayFeb 12, 2024 9:45 am

New MRI Procedure Eases Multiple Sclerosis Diagnosis

Researchers from ETH Zurich have developed a new magnetic resonance imaging (MRI) technique that can ease multiple sclerosis diagnosis and produce more accurate findings. Led by Emily Baadsvik and Markus Weiger from ETH Zurich’s Institute for Biomedical Engineering, the research team created a technique to map myelin sheath conditions for more accurate diagnoses. Multiple sclerosis (MS) is a potentially disabling neurological condition that affects the central nervous system (brain and spinal cord). It occurs when the immune system becomes dysfunctional and starts to attack myelin, the protective sheath that covers and protects nerve fibers, resulting in communication problems between the…

FridayFeb 09, 2024 11:00 am

The Right to Health During Humanitarian Crises Should Include Noncommunicable Diseases

Estimates from the United Nations show that about 363 million individuals worldwide are affected by humanitarian crises driven by the climate crisis, increase conflict and fragility, and broadening inequality. In 2022, more than 108 million individuals were forced to flee their homes due to conflict. While humanitarian crises such as those currently occurring in Gaza, Sudan, Libya, Somalia and Ukraine may vary in scale and nature, they all share infrastructure demolition, displacement of the masses, and the disruption of services and supply chains. Healthcare facilities are also heavily impacted in times of conflict, particularly because they are directly targeted. Access…

WednesdayFeb 07, 2024 10:15 am

Patients with Swelling Disorder See New Gene Therapy as Godsend

A new gene therapy is transforming the lives of patients with a debilitating hereditary condition that causes painful and even fatal levels of swelling. The therapy led to significantly promising results in its first trial involving humans, with patients involved in the study reporting “dramatic improvements” in their symptoms that allowed them to stop taking long-term medication and resume their regular day-to-day activities. Hereditary angioedema is a rare condition that arises from a genetic mutation and causes leaky blood vessels in patients. This leads to random bouts of swelling that can affect the hand, feet, throat, bowels, mouth and lips…

WednesdayFeb 07, 2024 9:00 am

Longeveron Inc.’s (NASDAQ: LGVN) Long-Term Follow-Up Data from Its ELPIS I Clinical Trial Presented at the 2023 Annual Scientific Sessions of the American Heart Association

A poster about Longeveron’s long-term follow-up data from its ELPIS I clinical trial was presented at the 2023 Scientific Sessions of the American Heart Association in November 2023 The poster showed that 100% of the 10 patients enrolled in the study survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-B(TM) during their Stage II surgery The data supports Longeveron’s ongoing ELPIS II study, which has exceeded its 50% enrollment threshold The company believes the long-term follow-up data underscore the potential for Lomecel-B(TM) as a much-needed therapeutic innovation for HLHS patients Historical results from outside…

TuesdayFeb 06, 2024 11:45 am

How AI Could Revolutionize Personalization in e-Commerce

According to a 2021 study by McKinsey & Company, 71% of customers expect companies to deliver personalized experiences while 78% choose to pay higher prices for personalized services or custom services. The study revealed that companies with great personalization earn roughly 40% more revenue from personalization-related activities compared to companies with average personalization. The research also found that 75% of customers recently tried a new shopping behavior, indicating that it is getting increasingly hard for brands to gain and retain customer loyalty. Personalization has become very important to customers who, on average, expect some degree of personalization in their interactions…

TuesdayFeb 06, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS

Clene recently reported new results from the open-label, long-term extension (“LTE”) of the VISIONARY-MS trial, involving participants with stable relapsing Multiple Sclerosis (“MS”) through week 144 (over 2.75 years) after the initial randomization Results from the 48-week double-blind period showed statistically significant improvements in vision (primary endpoint), as well as a combined improvement in cognition, walking speed, upper extremity function, and vision (secondary endpoint) with CNM-Au8 treatment, with further significant improvements in both vision and cognition extending throughout the 96-week LTE One of the trial’s key clinical advisors hailed the results as robust and consistent, describing the observed long-term clinical…

MondayFeb 05, 2024 12:00 pm

Astiva Health Differentiating Itself in Medicare Market, Working to Provide ‘Robust, Stable’ Offerings

CMS forecasts enrollment in Medicare Advantage programs will increase from 31.6 million in 2023 to 33.8 million in 2024 Astiva Health recently expanded into three Southern California counties, resulting in the company reaching the 10,000-member milestone mark Astiva is committed to reshape healthcare delivery, increased access to quality healthcare In a space where a growing number of individuals are qualifying for Medicare, Astiva Health is differentiating itself as a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan focused on redefining the standards of personalized and comprehensive healthcare. As an indication of its success in, Astiva company recently reached a key milestone, surpassing the…

MondayFeb 05, 2024 10:45 am

Scientists Start Trialing First Blood Test Against Brain Cancer

Brain tumors, which affects thousands of individuals around the globe, can be diagnosed using various imaging techniques, including magnetic resonance imaging (MRI) and computed tomography (CT) scans. Some tumors cannot be diagnosed using these techniques, however, which makes it hard for them to be detected earlier. In the United Kingdom, brain tumors kill more individuals aged 40 and below than any other cancer. Now, researchers have developed a blood test that may revolutionize the diagnosis of brain cancer. The blood test, called the TriNetra-Glio test, may help diagnose patients with different types of brain cancer earlier, which could eliminate the…